Emblem launches new line of Oil Capsules
Capsules are latest addition to the Company’s growing line of innovative medical cannabis products
TORONTO, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”), through its wholly-owned subsidiary Emblem Cannabis Corporation, today announced the launch of a new line of 10mg Emblem Oil Capsules, providing its growing list of 6,000+ patients with a pre-dosed treatment format. This convenient capsule formulation is designed to help patients better manage their treatment through precise dosing of their cannabis medication.
“Patient-focused treatment options are key drivers of Emblem’s innovation pipeline. As a patient-first provider, we’re continuing to develop products that meet our patients’ needs now and into the future,” said Nick Dean, CEO, Emblem Corp. “Accessing a variety of distribution channels is also a critical factor in our business strategy, and we are pleased to offer our medical cannabis products direct to patients through www.emblemcannabis.com, and soon through our supply agreement with Shoppers Drug Mart, which recently received its Federal Medical Sales License.”
“Patients want access to medical cannabis in formats that are discreet and easy-to-use, with established dosing,” added Wayne Kreppner, President of Medical, Emblem Corp. “The precision found in Emblem’s Oil Capsules addresses this and allows patients to easily track their medication and adjust as needed, while giving healthcare professionals another mode of administration that resembles traditional medications.”
The 10mg Emblem Oil Capsules offer a consistent patient experience formulated with three chemovar specific formats - High THC (10mg THC per capsule), High CBD (10 mg CBD per capsule) and Balanced (6mg THC/10 mg CBD per capsule). The capsules are odorless, flavourless and vegan, and suitable for patients already established on a cannabis oil dosage of 10mg or more. Patients can expect the same high quality in the Emblem Oil Capsules as found in the rest of Emblem's line of oil products, which includes Atmosphere oral dose-metered sprays and Emblem Oils.
Emblem plans to introduce additional dosage strengths of its oil capsules in the coming months to further address the medical needs of new patients or those wishing to titrate their dosage.
The Company would also like to note that the total number of issued and outstanding shares in the Company’s MD&A for the nine-month period ended September 30, 2018 referenced 123,606,221 common shares issued and outstanding as of the date of the filing of such MD&A. This number did not reflect the 6,952,169 shares issued to Aphria as was set out in the Company’s September 12, 2018 news release. As such, as of the date of the Company’s MD&A for the period ended September 30, 2018, the total issued and outstanding shares should have read 130,558,390 – such number also being the number of issued and outstanding shares as of the date of this news release.
Appointment of Officers
Emblem has formally appointed two new officers of the Company – Maria Guest, Chief Marketing Officer, and Karyn Sullivan, General Counsel & Secretary, both of whom joined Emblem earlier this year.
Emblem is a fully integrated cannabis company focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Through its wholly-owned subsidiary Emblem Cannabis Corporation, Emblem is licensed to cultivate, process, and sell cannabis and cannabis derivatives in Canada under the Cannabis Act. Emblem’s state-of-the-art indoor cannabis cultivation facility and Product Innovation Centre is located in Paris, Ontario. Emblem is also the parent company of GrowWise Health Limited, one of Canada’s leading cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.
For more information, please visit www.emblemcorp.com.
For media inquiries, please contact:
For investor inquiries, please contact:
Chief Financial Officer
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “may”, “will”, “project”, “should” or similar words, including negatives thereof, suggesting future outcomes. Management of the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date hereof but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. Various material factors and assumptions are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Those material factors and assumptions are based on information currently available to the Company, including data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which Emblem believes to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While Emblem is not aware of any misstatement regarding any industry or government data presented herein, the medical marijuana industry involves risks and uncertainties and is subject to change based on various factors.
Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company’s December 31, 2017 Management’s Discussion and Analysis, which has been filed with the Canadian Securities Administrators and available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Upcoming Life Sciences Events
- December 2018
- London: The Pharma Business Development Course - An Overview Course
- London: Genesis 2018
- January 2019
- San Francisco: Biotech Showcase